メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
藤田医科大学でコンテンツを検索
ホーム
プロファイル
研究部門
研究成果
Scopus著者プロファイル
中野 卓二
医学部・消化器内科学・第１
h-index
491
被引用数
13
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2008
2026
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(35)
類似のプロファイル
(9)
フィンガープリント
Takuji Nakanoが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Hepatocellular Carcinoma
75%
Bevacizumab
50%
Atezolizumab
50%
Endoscopic Ultrasound
48%
Progressive Disease
29%
Diseases
25%
Acoustic Radiation
24%
Cystic Pancreatic Lesion
24%
Chronic Hepatitis C
24%
Neoplasm
22%
Progression Free Survival
20%
Liver Function
15%
Transcatheter Arterial Chemoembolization
15%
Intraductal Papillary Mucinous Tumor
14%
Immune Checkpoint Inhibitor
14%
Liver Biopsy
14%
Transient Elastography
14%
Lenvatinib
13%
Diagnosis
13%
Chronic Hepatitis B
12%
Extrahepatic Bile Duct Obstruction
12%
Interferon
12%
Hypoalbuminemia
12%
Biloma
12%
Liver Cirrhosis
12%
Polyp
12%
MALT Lymphoma
12%
Branched Chain Amino Acid
12%
Cholangitis
12%
Cholestasis
12%
Hepatitis C Virus
12%
Common Bile Duct
12%
Bile Duct
12%
Nalfurafine
12%
Recurrent Disease
12%
Fibrosis
12%
Cisplatin
12%
Intraarterial Drug Administration
12%
Confocal Laser Scanning Microscopy
12%
Antiviral Therapy
12%
Combination Therapy
12%
Metabolic Dysfunction-Associated Steatohepatitis
12%
Cabozantinib
12%
Alpha-Fetoprotein
12%
Des-Gamma Carboxyprothrombin
12%
Biological Marker
12%
Treatment Response
12%
Overall Survival
11%
Ribavirin
10%
Oncology
9%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Bevacizumab
74%
Atezolizumab
74%
Diseases
53%
Alpha Fetoprotein
24%
Lenvatinib
23%
Phospholipase
20%
Progression Free Survival
19%
Immune Checkpoint Inhibitor
14%
Combination Therapy
13%
Solid Malignant Neoplasm
13%
Nonalcoholic Fatty Liver
12%
Antiviral Therapy
12%
Recurrent Disease
12%
Cisplatin
12%
Hepatitis B Antigen
12%
Interferon
12%
Extrahepatic Bile Duct Obstruction
12%
Hypoalbuminemia
12%
Chemotherapy
12%
Nalfurafine
12%
Chronic Hepatitis C
12%
Branched Chain Amino Acid
12%
Alpha Tocopherol
12%
Erythropoietic Protoporphyria
12%
Tremelimumab
12%
Cabozantinib
12%
Biological Marker
12%
Decarboxyprothrombin
12%
Disease
10%
Overall Survival
10%
Ribavirin
10%
Aspartate Aminotransferase
10%
Alanine
8%
Focused Ion Beam
8%
Guanosine Triphosphate
6%
Serum Albumin
5%
Keyphrases
Atezolizumab Plus Bevacizumab
36%
Advanced Hepatocellular Carcinoma
24%
Atezolizumab
22%
Lenvatinib
21%
Endoscopic Ultrasonography
14%
Intraductal Papillary mucinous Neoplasm
14%
Chronic Hepatitis B
12%
Antiretroviral Therapy
12%
Medical Ultrasonics
12%
Efficacy Predictor
12%
Liver Stiffness
12%
Biloma
12%
Bilirubin
12%
Intrahepatic Cholestasis
12%
Shear Wave Velocity
12%
Interferon-based Therapy
12%
Branched-chain Amino Acid Granules
12%
I148M
12%
PNPLA3
12%
Hepatitis B Envelope Antigen
12%
Acoustic Radiation Force Impulse Elastography
12%
Acoustic Radiation Force Impulse
12%
Stiffness Index
12%
Chronic Pruritus
12%
Nalfurafine Hydrochloride
12%
Contrast-enhanced Harmonic Endoscopic Ultrasonography
12%
Pancreatic Cyst
12%
Nutritional Status Assessment
12%
Intrahepatic Distant Recurrence
12%
Erythropoietic Protoporphyria
12%
Endoscopic Ultrasound
12%
Tremelimumab
12%
Complete Response
12%
Clinical Practice
12%
Combination Therapy
12%
Metabolic Dysfunction-associated Steatohepatitis
12%
Function Composition
12%
Early Progressive Disease
12%
Early Progression
12%
Hepatocellular Carcinoma
12%
Mural Nodule
9%
Hepatitis B Surface Antigen Levels
9%
Hepatocellular Carcinoma Progression
9%
Nalfurafine
9%
Bevacizumab
8%
Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
8%
Fibrosis-4 (FIB-4)
8%
Nutritional Risk Index
8%
Objective Response Rate
7%
Disease Control Rate
7%
